BGB 283

Drug Profile

BGB 283

Alternative Names: BeiGene 283; BGB-283

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator BeiGene
  • Developer BeiGene; Merck Serono
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 May 2016 Chemical information added
  • 17 Apr 2016 Interim Safety, efficacy and pharmacoknetics data from a phase I trial were presented by BeiGene at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016) .
  • 16 Apr 2016 Pharmacodynamics data from preclinical trials in cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016) (3182690; 3183722)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top